Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)
Keros Therapeutics (KROS) posted Cash from Financing Activities of -$378.6 million for Q4 2025, down 270550.71% on a QoQ basis from $140000.0 in Q3 2025, and down 601.21% year-over-year from $75.5 million in Q4 2024.
Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Keros Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$378.6 million for Q4 2025.
- Quarterly Cash from Financing Activities fell 601.21% year-over-year to -$378.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$378.5 million (down 196.59% YoY) and the FY2025 annual result came in at -$378.5 million, down 196.59% from the prior year.
- Cash from Financing Activities was -$378.6 million for Q4 2025 at Keros Therapeutics, down from $140000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $156.8 million in Q1 2024 and bottomed at -$378.6 million in Q4 2025.
- A 5-year average of $17.1 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 138708.57% — and 2025, when it tumbled 601.21%.
- Keros Therapeutics' Cash from Financing Activities stood at $28.4 million in 2021, then surged by 116.13% to $61.4 million in 2022, then climbed by 12.76% to $69.3 million in 2023, then climbed by 9.08% to $75.5 million in 2024, then tumbled by 601.21% to -$378.6 million in 2025.
- Business Quant data shows KROS's Cash from Financing Activities at -$378.6 million in Q4 2025, $140000.0 in Q3 2025, and $17000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | -378.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -378.63 Mn |
| Dec 31, 2025 | -378.63 Mn |
| Sep 30, 2025 | 140,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 75.54 Mn |
| Dec 31, 2024 | 75.54 Mn |
| Sep 30, 2024 | 155.94 Mn |
| Sep 30, 2024 | 155.94 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 156.80 Mn |
| Mar 31, 2024 | 156.80 Mn |
| Dec 31, 2023 | 69.25 Mn |
| Dec 31, 2023 | 69.25 Mn |
| Sep 30, 2023 | 284,000.00 |
| Sep 30, 2023 | 284,000.00 |